Sheela Jitendra Huff

Array ( [id] => 14309719 [patent_doc_number] => 20190144563 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => T CELL RECEPTOR-LIKE ANTIBODIES SPECIFIC FOR A WTI PEPTIDE PRESENTED BY HLA-A2 [patent_app_type] => utility [patent_app_number] => 16/055535 [patent_app_country] => US [patent_app_date] => 2018-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16006 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16055535 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13589999 [patent_doc_number] => 20180346548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-06 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS [patent_app_type] => utility [patent_app_number] => 16/055796 [patent_app_country] => US [patent_app_date] => 2018-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48442 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 256 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16055796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13574785 [patent_doc_number] => 20180338941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/050441 [patent_app_country] => US [patent_app_date] => 2018-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7952 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16050441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17727764 [patent_doc_number] => 11384139 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-12 [patent_title] => Antibody targeting cell surface deposited complement protein C3d and use thereof [patent_app_type] => utility [patent_app_number] => 16/047929 [patent_app_country] => US [patent_app_date] => 2018-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 9408 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16047929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13929115 [patent_doc_number] => 20190048073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-14 [patent_title] => ANTI-GD3 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/039852 [patent_app_country] => US [patent_app_date] => 2018-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16039852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15848225 [patent_doc_number] => 10639373 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-05 [patent_title] => Pyrrolobenzodiazepine antibody drug conjugates and methods of use [patent_app_type] => utility [patent_app_number] => 16/036575 [patent_app_country] => US [patent_app_date] => 2018-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 22 [patent_no_of_words] => 55164 [patent_no_of_claims] => 48 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16036575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13574783 [patent_doc_number] => 20180338940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-29 [patent_title] => IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/034123 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26493 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13823757 [patent_doc_number] => 20190015363 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => RECEPTOR SUBTYPE AND FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/034064 [patent_app_country] => US [patent_app_date] => 2018-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12780 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16034064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13519575 [patent_doc_number] => 20180311330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-01 [patent_title] => Novel immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML) [patent_app_type] => utility [patent_app_number] => 16/032231 [patent_app_country] => US [patent_app_date] => 2018-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16032231 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16369082 [patent_doc_number] => 10800823 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-10-13 [patent_title] => Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers [patent_app_type] => utility [patent_app_number] => 16/026707 [patent_app_country] => US [patent_app_date] => 2018-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 46 [patent_no_of_words] => 41130 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16026707 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926377 [patent_doc_number] => 20190298826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => COMBINATION THERAPIES FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/023347 [patent_app_country] => US [patent_app_date] => 2018-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16023347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13840579 [patent_doc_number] => 20190023774 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => Methods and Compositions for Targeting Polyubiquitin [patent_app_type] => utility [patent_app_number] => 16/021248 [patent_app_country] => US [patent_app_date] => 2018-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46796 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16021248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13490293 [patent_doc_number] => 20180296689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-18 [patent_title] => NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES [patent_app_type] => utility [patent_app_number] => 16/018567 [patent_app_country] => US [patent_app_date] => 2018-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39769 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16018567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13986541 [patent_doc_number] => 20190062428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH-INDUCING AGENTS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/012538 [patent_app_country] => US [patent_app_date] => 2018-06-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49021 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16012538 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13457851 [patent_doc_number] => 20180280468 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => TREATMENT OF PRIMARY AND METASTATIC CARCINOMA [patent_app_type] => utility [patent_app_number] => 16/007727 [patent_app_country] => US [patent_app_date] => 2018-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7010 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16007727 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733261 [patent_doc_number] => 20180371098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => ANTI-JAGGED1 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 15/997299 [patent_app_country] => US [patent_app_date] => 2018-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34741 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15997299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13867643 [patent_doc_number] => 20190030162 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-31 [patent_title] => Combination Therapies Employing GITR Binding Molecules [patent_app_type] => utility [patent_app_number] => 15/990401 [patent_app_country] => US [patent_app_date] => 2018-05-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15990401 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13399927 [patent_doc_number] => 20180251506 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 15/980328 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 102366 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 262 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15980328 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13563911 [patent_doc_number] => 20180333503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-11-22 [patent_title] => ANTI-FOLR1 IMMUNOCONJUGATES AND ANTI-PD-1 ANTIBODY COMBINATIONS [patent_app_type] => utility [patent_app_number] => 15/979989 [patent_app_country] => US [patent_app_date] => 2018-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15979989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13265377 [patent_doc_number] => 10144763 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-12-04 [patent_title] => Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL) [patent_app_type] => utility [patent_app_number] => 15/965212 [patent_app_country] => US [patent_app_date] => 2018-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 41 [patent_no_of_words] => 51097 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 169 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15965212 [rel_patent_id] =>[rel_patent_doc_number] =>)